MXCT
MAXCYTE, INC.
$1.15
+0.88%
$123.2M
No data for this timeframe.
Vol
Market Cap$123.2M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (77%)
Inst. Holders8 funds
Inst. Value$17.9M
Inst. Activity4 buys / 1 sells
Insider Activity0B / 1S
Insider Net $-$8.3K
SEC Reports1
Press Releases1
Exchange Nasdaq·Sector Services-Commercial Physical & Biological Research·Inc. DE·CIK 0001287098·Prev Close $1.14
Recent Activity
May 12, 2026
earnings_calendar
MXCT Q1 2026 Earnings Scheduled — 2026-05-12
Apr 29, 2026
SEC
MaxCyte filed DEFA14A additional proxy soliciting materials. Document content is unavailable, but filing type suggests o
DEFA14A — Impact 2/10
Apr 15, 2026
Insider
Ahuja Parmeet sold 187,500 shares
Chief Financial Officer @ $0.00 ($0.00)
Mar 30, 2026
Insider
Ahuja Parmeet sold 375,000 shares
Chief Financial Officer @ $0.00 ($0.00)
Mar 27, 2026
Insider
Masoud Maher sold 600,000 shares
President and CEO @ $0.00 ($0.00)
Inst.
MORGAN STANLEY — TRIM
4,433,693 shares ($6.9M)
Inst.
CHARLES SCHWAB INVESTMENT MANAGEMENT — ADD
369,701 shares ($573.0K)
Mar 24, 2026
Press
MaxCyte reported Q4 and full-year 2025 results with total revenue of $7.3M and $33.0M, respectively, representing 16% an
Impact 7/10
Price Targets
$4.11
+245.2% upside
Strong Buy
Current $1.19
Low $2.43
Median $4.50
High $5.00
4 analysts
$2.43
$5.00
Analyst Ratings
5Strong Buy
5Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 25, 2026 | Craig-Hallum | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.09 | $-0.12 — $-0.08 | 22% YoY | 3 |
| Next Q | $-0.08 | $-0.08 — $-0.07 | 13% YoY | 3 |
| Current FY | $-0.27 ▲ +5.0% | $-0.29 — $-0.26 | 23% YoY | 3 |
| Next FY | $-0.25 ▲ +7.4% | $-0.29 — $-0.23 | 9% YoY | 4 |
Latest Reports
NEUTRAL
DEFA14A
2/10
MaxCyte filed DEFA14A additional proxy soliciting materials. Document content is unavailable, but filing type suggests o
Apr 29, 2026
BEARISH
Press
7/10
MaxCyte reported Q4 and full-year 2025 results with total revenue of $7.3M and $33.0M, respectively, representing 16% an
Mar 24, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $8.6M | — |
| MORGAN STANLEY | $6.9M | TRIM |
| RENAISSANCE TECHNOLOGIES LLC | $1.2M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $573.0K | ADD |
| FMR LLC | $223.8K | NEAR_EXIT |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 15, 2026 | Ahuja Parmeet | A | $0.00 |
| Mar 30, 2026 | Ahuja Parmeet | A | $0.00 |
| Mar 27, 2026 | Masoud Maher | A | $0.00 |
| Mar 27, 2026 | Masoud Maher | A | $0.00 |
| Mar 17, 2026 | Swirsky Douglas | SELL | $8.3K |
8 institutional holders with $17.9M total value (11,573,040 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, RENAISSANCE. Net buying activity: 4 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 5,539,260 | $8.6M | 47.9% | — |
| 2 | MORGAN STANLEY | 4,433,693 | $6.9M | 38.3% | TRIM -33.8% |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 786,900 | $1.2M | 6.8% | ADD +95.1% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 369,701 | $573.0K | 3.2% | ADD +46.6% |
| 5 | FMR LLC | 144,386 | $223.8K | 1.2% | NEAR_EXIT -93.1% |
| 6 | WELLS FARGO & COMPANY/MN | 113,381 | $175.7K | 1.0% | ADD +46.2% |
| 7 | BANK OF AMERICA CORP /DE/ | 97,801 | $151.6K | 0.8% | ADD +35.5% |
| 8 | TWO SIGMA INVESTMENTS, LP | 87,918 | $136.3K | 0.8% | NEW |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | TRIM | 6,695,879 | 4,433,693 | -33.8% | $6.9M | 2025-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 252,230 | 369,701 | +46.6% | $573.0K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 77,536 | 113,381 | +46.2% | $175.7K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 72,164 | 97,801 | +35.5% | $151.6K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 87,918 | — | $136.3K | 2025-Q4 |
| UBS Group AG | DOUBLED | 165,718 | 474,487 | +186.3% | $749.7K | 2025-Q3 |
| FMR LLC | NEAR_EXIT | 1,935,181 | 133,936 | -93.1% | $211.6K | 2025-Q3 |
| FMR LLC | TRIM | 2,944,970 | 1,935,181 | -34.3% | $4.2M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 367,900 | 717,800 | +95.1% | $1.6M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | ADD | 55,065 | 84,836 | +54.1% | $184.9K | 2025-Q2 |
| MORGAN STANLEY | ADD | 4,408,253 | 7,000,799 | +58.8% | $19.1M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 281,200 | 367,900 | +30.8% | $1.0M | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 392,298 | 237,642 | -39.4% | $648.8K | 2025-Q1 |
| UBS Group AG | ADD | 110,646 | 203,287 | +83.7% | $555.0K | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 53,573 | 392,298 | +632.3% | $1.6M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 190,100 | 281,200 | +47.9% | $1.2M | 2024-Q4 |
| UBS Group AG | ADD | 68,051 | 110,646 | +62.6% | $460.3K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 48,035 | 61,411 | +27.8% | $255.5K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 299,673 | — | $1.2M | 2024-Q3 |
3 unique insiders with 1 transactions. Net insider value: -$8.3K ($0.00 bought, $8.3K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 15, 2026 | Ahuja Parmeet | Chief Financial Officer | A | 187,500 | $0.00 | $0.00 |
| Mar 30, 2026 | Ahuja Parmeet | Chief Financial Officer | A | 375,000 | $0.00 | $0.00 |
| Mar 27, 2026 | Masoud Maher | President and CEO | A | 600,000 | $0.00 | $0.00 |
| Mar 27, 2026 | Masoud Maher | President and CEO | A | 300,000 | $0.00 | $0.00 |
| Mar 17, 2026 | Swirsky Douglas J | CHIEF FINANCIAL OFFICER | SELL | 10,142 | $0.8150 | $8.3K |
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 2.0/10.
Current analyst consensus: Buy (77% buy). Based on 13 analysts: 5 strong buy, 5 buy, 3 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$4.11 mean target
+245.2% upside
Strong Buy (3.00)
$2.43 Low
$5.00 High
| Metric | Value |
|---|---|
| Current Price | $1.19 |
| Target Low | $2.43 |
| Target Mean | $4.11 |
| Target Median | $4.50 |
| Target High | $5.00 |
| # Analysts | 4 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.09 | $-0.12 | $-0.08 | 22.2% | — | 0↑ 1↓ | $0.0B | -22.1% | 3 |
| Next Q 2026-09-30 |
$-0.08 | $-0.08 | $-0.07 | 12.7% | — | 0↑ 1↓ | $0.0B | 3.9% | 3 |
| Current FY 2026-12-31 |
$-0.27 | $-0.29 | $-0.26 | 23.0% | +5.0% | 1↑ 1↓ | $0.0B | -5.9% | 3 |
| Next FY 2027-12-31 |
$-0.25 | $-0.29 | $-0.23 | 9.4% | +7.4% | 2↑ 0↓ | $0.0B | 20.9% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.093 | |
| 7d ago | $0.000 | -0.093 |
| 30d ago | $0.000 | -0.093 |
| 60d ago | $-0.070 | -0.023 |
| 90d ago | $-0.070 | -0.023 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 25, 2026 | Craig-Hallum | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 5 | 3 | 0 | 0 | 77% | |
| May 1, 2026 | 5 | 5 | 3 | 0 | 0 | 77% | |
| Apr 1, 2026 | 5 | 5 | 3 | 0 | 0 | 77% | |
| Mar 1, 2026 | 5 | 5 | 3 | 0 | 0 | 77% | |
| Feb 1, 2026 | 5 | 5 | 3 | 0 | 0 | 77% | |
| Jan 1, 2026 | 5 | 5 | 3 | 0 | 0 | 77% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 12, 2026
earnings_calendar
MXCT Q1 2026 Earnings Scheduled — 2026-05-12
May 4, 2026
earnings_calendar
MXCT Q1 2026 Earnings Scheduled — 2026-05-04
Apr 10, 2026
short_volume
Short Volume: MXCT — 56.7% short (0.4M / 0.7M)
Short: 373,974 | Exempt: 0 | TRF Vol: 659,565 | Short Ratio: 56.7% | Off-exchange volume (dark pool + OTC)
Mar 25, 2026
short_volume
Short Volume: MXCT — 58.6% short (0.6M / 1.0M)
Short: 592,454 | Exempt: 380 | TRF Vol: 1,010,508 | Short Ratio: 58.6% | Off-exchange volume (dark pool + OTC)
Mar 24, 2026
earnings
MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance
<p align="center"><em>Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement</em></p>
Mar 24, 2026
earnings_calendar
MXCT Q4 2025 Earnings After Market Close — 2026-03-24
Mar 23, 2026
other
MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer
<p>ROCKVILLE, Md., March 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling pl